From adtech to healthtech, Jonathon Wolf has built ZOE into one of the world’s leading nutrition science companies, translating cutting-edge microbiome research into tools that help millions improve their health. We sat down with Jonathon to explore how ZOE turns complex science into daily action, what it takes to build trust at the intersection of research and consumers, and why personalised nutrition could redefine preventative healthcare.
All content for What's Next is the property of Balderton Capital and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
From adtech to healthtech, Jonathon Wolf has built ZOE into one of the world’s leading nutrition science companies, translating cutting-edge microbiome research into tools that help millions improve their health. We sat down with Jonathon to explore how ZOE turns complex science into daily action, what it takes to build trust at the intersection of research and consumers, and why personalised nutrition could redefine preventative healthcare.
Uncommon is using ground-breaking RNA cell technology to tackle the most pressing challenges to our health, starting with cultivated pork. Co-founder and CEO Benjamina Bollag sat down with James Wise to break down how cultivated meat will help tackle not only climate challenges, but also help improve global public health. Find out more about Uncommon here and follow them on LinkedIn Find Balderton Capital here and follow us on LinkedIn
What's Next
From adtech to healthtech, Jonathon Wolf has built ZOE into one of the world’s leading nutrition science companies, translating cutting-edge microbiome research into tools that help millions improve their health. We sat down with Jonathon to explore how ZOE turns complex science into daily action, what it takes to build trust at the intersection of research and consumers, and why personalised nutrition could redefine preventative healthcare.
